Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria

Marcus J Rijken; Rose McGready; Vincent Jullien; Joel Tarning; Niklas Lindegardh; Aung Pyae Phyo; Aye Kyi Win; Poe Hsi; Mireille Cammas; Pratap Singhasivanon; Nicholas J. White; François Nosten

doi:10.1128/AAC.00154-11

Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria

Marcus J Rijken, Rose McGready, Vincent Jullien, Joel Tarning, Niklas Lindegardh, Aung Pyae Phyo, Aye Kyi Win, Poe Hsi, Mireille Cammas, Pratap Singhasivanon, Nicholas J. White, François Nosten

Birth Center Obstetrics - Medical

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In order to study the pharmacokinetic properties of amodiaquine and desethylamodiaquine during pregnancy, 24 pregnant women in the second and third trimesters of pregnancy and with Plasmodium vivax malaria were treated with amodiaquine (10 mg/kg of body weight/day) for 3 days. The same women were studied again at 3 months postpartum. Plasma was analyzed for amodiaquine and desethylamodiaquine by use of a liquid chromatography-tandem mass spectrometry method. Individual concentration-time data were evaluated using noncompartmental analysis. There were no clinically relevant differences in the pharmacokinetics of amodiaquine and desethylamodiaquine between pregnant (n = 24) and postpartum (n = 18) women. The results suggest that the current amodiaquine dosing regimen is adequate for the treatment of P. vivax infections during pregnancy.

Original language	English
Pages (from-to)	4338-42
Number of pages	5
Journal	Antimicrobial Agents and Chemotherapy
Volume	55
Issue number	9
DOIs	https://doi.org/10.1128/AAC.00154-11
Publication status	Published - Sept 2011

Keywords

Adolescent
Adult
Amodiaquine
Antimalarials
Female
Humans
Malaria, Vivax
Postpartum Period
Pregnancy
Young Adult
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Access to Document

10.1128/AAC.00154-11

Cite this

Rijken, M. J., McGready, R., Jullien, V., Tarning, J., Lindegardh, N., Phyo, A. P., Win, A. K., Hsi, P., Cammas, M., Singhasivanon, P., White, N. J., & Nosten, F. (2011). Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria. Antimicrobial Agents and Chemotherapy, 55(9), 4338-42. https://doi.org/10.1128/AAC.00154-11

@article{f3d6e8937f8e45a2aed3750c252ece4a,

title = "Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria",

abstract = "In order to study the pharmacokinetic properties of amodiaquine and desethylamodiaquine during pregnancy, 24 pregnant women in the second and third trimesters of pregnancy and with Plasmodium vivax malaria were treated with amodiaquine (10 mg/kg of body weight/day) for 3 days. The same women were studied again at 3 months postpartum. Plasma was analyzed for amodiaquine and desethylamodiaquine by use of a liquid chromatography-tandem mass spectrometry method. Individual concentration-time data were evaluated using noncompartmental analysis. There were no clinically relevant differences in the pharmacokinetics of amodiaquine and desethylamodiaquine between pregnant (n = 24) and postpartum (n = 18) women. The results suggest that the current amodiaquine dosing regimen is adequate for the treatment of P. vivax infections during pregnancy.",

keywords = "Adolescent, Adult, Amodiaquine, Antimalarials, Female, Humans, Malaria, Vivax, Postpartum Period, Pregnancy, Young Adult, Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't",

author = "Rijken, {Marcus J} and Rose McGready and Vincent Jullien and Joel Tarning and Niklas Lindegardh and Phyo, {Aung Pyae} and Win, {Aye Kyi} and Poe Hsi and Mireille Cammas and Pratap Singhasivanon and White, {Nicholas J.} and Fran{\c c}ois Nosten",

year = "2011",

month = sep,

doi = "10.1128/AAC.00154-11",

language = "English",

volume = "55",

pages = "4338--42",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "9",

}

Rijken, MJ, McGready, R, Jullien, V, Tarning, J, Lindegardh, N, Phyo, AP, Win, AK, Hsi, P, Cammas, M, Singhasivanon, P, White, NJ & Nosten, F 2011, 'Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria', Antimicrobial Agents and Chemotherapy, vol. 55, no. 9, pp. 4338-42. https://doi.org/10.1128/AAC.00154-11

TY - JOUR

T1 - Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria

AU - Rijken, Marcus J

AU - McGready, Rose

AU - Jullien, Vincent

AU - Tarning, Joel

AU - Lindegardh, Niklas

AU - Phyo, Aung Pyae

AU - Win, Aye Kyi

AU - Hsi, Poe

AU - Cammas, Mireille

AU - Singhasivanon, Pratap

AU - White, Nicholas J.

AU - Nosten, François

PY - 2011/9

Y1 - 2011/9

N2 - In order to study the pharmacokinetic properties of amodiaquine and desethylamodiaquine during pregnancy, 24 pregnant women in the second and third trimesters of pregnancy and with Plasmodium vivax malaria were treated with amodiaquine (10 mg/kg of body weight/day) for 3 days. The same women were studied again at 3 months postpartum. Plasma was analyzed for amodiaquine and desethylamodiaquine by use of a liquid chromatography-tandem mass spectrometry method. Individual concentration-time data were evaluated using noncompartmental analysis. There were no clinically relevant differences in the pharmacokinetics of amodiaquine and desethylamodiaquine between pregnant (n = 24) and postpartum (n = 18) women. The results suggest that the current amodiaquine dosing regimen is adequate for the treatment of P. vivax infections during pregnancy.

AB - In order to study the pharmacokinetic properties of amodiaquine and desethylamodiaquine during pregnancy, 24 pregnant women in the second and third trimesters of pregnancy and with Plasmodium vivax malaria were treated with amodiaquine (10 mg/kg of body weight/day) for 3 days. The same women were studied again at 3 months postpartum. Plasma was analyzed for amodiaquine and desethylamodiaquine by use of a liquid chromatography-tandem mass spectrometry method. Individual concentration-time data were evaluated using noncompartmental analysis. There were no clinically relevant differences in the pharmacokinetics of amodiaquine and desethylamodiaquine between pregnant (n = 24) and postpartum (n = 18) women. The results suggest that the current amodiaquine dosing regimen is adequate for the treatment of P. vivax infections during pregnancy.

KW - Adolescent

KW - Adult

KW - Amodiaquine

KW - Antimalarials

KW - Female

KW - Humans

KW - Malaria, Vivax

KW - Postpartum Period

KW - Pregnancy

KW - Young Adult

KW - Clinical Trial

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1128/AAC.00154-11

DO - 10.1128/AAC.00154-11

M3 - Article

C2 - 21709098

SN - 0066-4804

VL - 55

SP - 4338

EP - 4342

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 9

ER -

Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria

Abstract

Keywords

Access to Document

Fingerprint

Cite this